Since the 1960's treatments for Parkinson's disease (PD) have traditionally been directed to
restore or replace dopamine, with L-Dopa being the gold standard. However, chronic L …

Among neurological adverse reactions in patients with schizophrenia treated with
antipsychotics (APs), drug-induced parkinsonism (DIP) is the most common motility disorder …

Many cancer survivors suffer from chemotherapy-induced cognitive impairment known as
'Chemobrain'. Doxorubicin-topoisomerase II inhibitor-is widely used in breast cancer …

Abstract Ethnopharmacological relevance Thunbergia erecta (Benth.) was traditionally used
as anxiolytic, sedative and antidepressant. Aim of the study The study aimed to characterize …

Subcutaneous administration of rotenone has recently attracted attention because of its
convenience, simplicity and efficacy in replicating features of Parkinson's disease (PD) in …

Tardive dyskinesia (TD) is a motor disorder of the orofacial region resulting from chronic
neuroleptic treatment. A high incidence and irreversibility of this hyperkinetic disorder has …

Parkinson's disease (PD) is the second most common progressive neurodegenerative
disorder. Although mounting studies have been conducted, no effective therapy is available …

Parkinson's disease (PD) is a slowly progressive neurodegenerative movement disorder.
Apoptosis, neuroinflammation, and oxidative stress are the current hypothesized …

Aim Schizophrenia is a chronic, disabling and one of the major neurological illnesses
affecting nearly 1% of the global population. Currently available antipsychotic medications …

Parkinson's disease (PD) a neurodegenerative disorder for which no preventive or long-term
effective treatment strategies are available. Epidemiologic studies have failed to identify …